CT Imaging for Guiding PA-TACE for HCC
CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Li, MD
- Phone Number: 86-020-62783269
- Email: lixinmingsmu@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510280
- ZhuJiang Hospital of Southern Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- CT scans acquired no more than one month before surgery
- Confirmation of HCC diagnosis by pathological examination
- Curative surgical resection
Exclusion Criteria:
- Prior antitumor treatment
- Macrovascular thrombosis or metastasis
- Perioperative mortality
- Unqualified image artifacts
- Tumor rupture
- MVI status not reported
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Hepatectomy alone
|
HCC patients received hepatectomy and PA-TACE.
|
|
PA-TACE
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.
|
Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.
|
the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2019-KY-021-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.